155 related articles for article (PubMed ID: 25656821)
1. Association of Wnt-Inducible Signaling Pathway Protein 1 Genetic Polymorphisms With Lung Cancer Susceptibility and Platinum-Based Chemotherapy Response.
Chen J; Yin JY; Li XP; Wang Y; Zheng Y; Qian CY; He H; Fang C; Wang Z; Zhang Y; Xiao L; Wang SY; Zhang W; Zhou HH; Liu ZQ
Clin Lung Cancer; 2015 Jul; 16(4):298-304.e1-2. PubMed ID: 25656821
[TBL] [Abstract][Full Text] [Related]
2. WISP1 polymorphisms contribute to platinum-based chemotherapy toxicity in lung cancer patients.
Chen J; Yin J; Li X; Wang Y; Zheng Y; Qian C; Xiao L; Zou T; Wang Z; Liu J; Zhang W; Zhou H; Liu Z
Int J Mol Sci; 2014 Nov; 15(11):21011-27. PubMed ID: 25405734
[TBL] [Abstract][Full Text] [Related]
3. Association Between Genetic Polymorphisms of WNT1 Inducible Signaling Pathway Protein 1 and Uterine Cervical Cancer.
Lin YH; Hsiao YH; Yang SF; Liu YF; Hsu CF; Wang PH
Reprod Sci; 2018 Nov; 25(11):1549-1556. PubMed ID: 29402200
[TBL] [Abstract][Full Text] [Related]
4. Impact of WNT1-inducible signaling pathway protein-1 (WISP-1) genetic polymorphisms and clinical aspects of breast cancer.
Wang Y; Yang SH; Hsu PW; Chien SY; Wang CQ; Su CM; Dong XF; Zhao YM; Tang CH
Medicine (Baltimore); 2019 Nov; 98(44):e17854. PubMed ID: 31689877
[TBL] [Abstract][Full Text] [Related]
5. Impacts of WNT1-inducible signaling pathway protein 1 polymorphism on hepatocellular carcinoma development.
Chen CT; Lee HL; Chiou HL; Chou CH; Wang PH; Yang SF; Chou YE
PLoS One; 2018; 13(6):e0198967. PubMed ID: 29889892
[TBL] [Abstract][Full Text] [Related]
6. WISP1 genetic variants as predictors of tumor development with urothelial cell carcinoma.
Lee HL; Chiou HL; Wang SS; Hung SC; Chou MC; Yang SF; Hsieh MJ; Chou YE
Urol Oncol; 2018 Apr; 36(4):160.e15-160.e21. PubMed ID: 29277583
[TBL] [Abstract][Full Text] [Related]
7. [Correlation of genetic polymorphisms in nucleotide excision repair system to sensitivity of advanced non-small cell lung cancer patients to platinum-based chemotherapy].
Yuan P; Miao XP; Zhang XM; Wang ZH; Tan W; Zhang XR; Sun Y; Xu BH; Lin DX
Ai Zheng; 2005 Dec; 24(12):1510-3. PubMed ID: 16351803
[TBL] [Abstract][Full Text] [Related]
8. Association of genetic variations in the Wnt signaling pathway genes with myocardial infarction susceptibility in Chinese Han population.
Tao J; Wang YT; Abudoukelimu M; Yang YN; Li XM; Xie X; Chen BD; Liu F; He CH; Li HY; Ma YT
Oncotarget; 2016 Aug; 7(33):52740-52750. PubMed ID: 27391264
[TBL] [Abstract][Full Text] [Related]
9. Effect of polymorphisms in XPD on clinical outcomes of platinum-based chemotherapy for Chinese non-small cell lung cancer patients.
Wu W; Li H; Wang H; Zhao X; Gao Z; Qiao R; Zhang W; Qian J; Wang J; Chen H; Wei Q; Han B; Lu D
PLoS One; 2012; 7(3):e33200. PubMed ID: 22479369
[TBL] [Abstract][Full Text] [Related]
10. Associations of genetic polymorphisms of the transporters organic cation transporter 2 (OCT2), multidrug and toxin extrusion 1 (MATE1), and ATP-binding cassette subfamily C member 2 (ABCC2) with platinum-based chemotherapy response and toxicity in non-small cell lung cancer patients.
Qian CY; Zheng Y; Wang Y; Chen J; Liu JY; Zhou HH; Yin JY; Liu ZQ
Chin J Cancer; 2016 Sep; 35(1):85. PubMed ID: 27590272
[TBL] [Abstract][Full Text] [Related]
11. Association of ABCC2 polymorphisms with platinum-based chemotherapy response and severe toxicity in non-small cell lung cancer patients.
Han B; Gao G; Wu W; Gao Z; Zhao X; Li L; Qiao R; Chen H; Wei Q; Wu J; Lu D
Lung Cancer; 2011 May; 72(2):238-43. PubMed ID: 20943283
[TBL] [Abstract][Full Text] [Related]
12. Effect of genetic variation in microRNA binding site in WNT1-inducible signaling pathway protein 1 gene on oral squamous cell carcinoma susceptibility.
Lau HK; Wu ER; Chen MK; Hsieh MJ; Yang SF; Wang LY; Chou YE
PLoS One; 2017; 12(4):e0176246. PubMed ID: 28426731
[TBL] [Abstract][Full Text] [Related]
13. Genetic Variants of the MDM2 Gene Are Predictive of Treatment-Related Toxicities and Overall Survival in Patients With Advanced NSCLC.
Qian J; Liu H; Gu S; Wu Q; Zhao X; Wu W; Wang H; Wang J; Chen H; Zhang W; Wei Q; Jin L; Lu D
Clin Lung Cancer; 2015 Sep; 16(5):e37-53. PubMed ID: 25818095
[TBL] [Abstract][Full Text] [Related]
14. Genetic polymorphism of copper transporter protein 1 is related to platinum resistance in Chinese non-small cell lung carcinoma patients.
Xu X; Duan L; Zhou B; Ma R; Zhou H; Liu Z
Clin Exp Pharmacol Physiol; 2012 Sep; 39(9):786-92. PubMed ID: 22725681
[TBL] [Abstract][Full Text] [Related]
15. Prediction models for platinum-based chemotherapy response and toxicity in advanced NSCLC patients.
Yin JY; Li X; Li XP; Xiao L; Zheng W; Chen J; Mao CX; Fang C; Cui JJ; Guo CX; Zhang W; Gao Y; Zhang CF; Chen ZH; Zhou H; Zhou HH; Liu ZQ
Cancer Lett; 2016 Jul; 377(1):65-73. PubMed ID: 27126360
[TBL] [Abstract][Full Text] [Related]
16. Rho GTPases: RAC1 polymorphisms affected platinum-based chemotherapy toxicity in lung cancer patients.
Zou T; Yin J; Zheng W; Xiao L; Tan L; Chen J; Wang Y; Li X; Qian C; Cui J; Zhang W; Zhou H; Liu Z
Cancer Chemother Pharmacol; 2016 Aug; 78(2):249-58. PubMed ID: 27299748
[TBL] [Abstract][Full Text] [Related]
17. The genotype of ribonucleotidereductase M1 -269C > A is associated with the response to platinum-based chemotherapy and as a prognostic biomarker in advanced nonsmall cell lung cancer.
Xu XL; Zhang YP; Fang Y; Su D; Chen W; Feng JG; Li ZP; Mao WM
J Cancer Res Ther; 2015 Aug; 11 Suppl 1():C49-55. PubMed ID: 26323924
[TBL] [Abstract][Full Text] [Related]
18. Polymorphisms in the base excision repair pathway modulate prognosis of platinum-based chemotherapy in advanced non-small cell lung cancer.
Zhao W; Hu L; Xu J; Shen H; Hu Z; Ma H; Shu Y; Shao Y; Yin Y
Cancer Chemother Pharmacol; 2013 May; 71(5):1287-95. PubMed ID: 23479135
[TBL] [Abstract][Full Text] [Related]
19. Association of positively selected eIF3a polymorphisms with toxicity of platinum-based chemotherapy in NSCLC patients.
Yin JY; Meng XG; Qian CY; Li XP; Chen J; Zheng Y; Liu R; Zhou HH; Liu ZQ
Acta Pharmacol Sin; 2015 Mar; 36(3):375-84. PubMed ID: 25732572
[TBL] [Abstract][Full Text] [Related]
20. First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer.
Shen L; Qiang T; Li Z; Ding D; Yu Y; Lu S
Cancer Med; 2020 May; 9(10):3310-3318. PubMed ID: 32167664
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
